Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

Item

http://www.wikidata.org/entity/Q45347178

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

@en

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

@nl

type

Item

label

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

@en

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

@nl

prefLabel

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

@en

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

@nl

P1476

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

@en

P2093

J Scott Andrews

http://www.w3.org/2001/XMLSchema#string

Megha Bansal

http://www.w3.org/2001/XMLSchema#string

Michael Happich

http://www.w3.org/2001/XMLSchema#string

Robert W Klein

http://www.w3.org/2001/XMLSchema#string

Ronald C Wielage

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis

Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

An economic model of long-term use of celecoxib in patients with osteoarthritis

Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

Hepatic effects of duloxetine-I: non-clinical and clinical trial data.

Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources.

P2888

s40258-013-0031-3

P304

219-236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40258-013-0031-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236328666

http://www.w3.org/2001/XMLSchema#string

P6179

1041165909

http://www.w3.org/2001/XMLSchema#string

P698

23616247

http://www.w3.org/2001/XMLSchema#string

P921

osteoarthritis